The long-term prognostic significance of heart failure in sarcoidosis patients ─ a cohort study

References

• Statement on Sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER. Am J Respir Crit Care Med. 1999;160:736–755.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of Sarcoidosis. An official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201:e26–e51.
   PubMed Web of Science ®Google Scholar
• Doughan AR. Cardiac sarcoidosis. Heart. 2006;92:282–288.
   PubMed Web of Science ®Google Scholar
• Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults: cardiac sarcoidosis presenting as atrioventricular block. J Cardiovasc Electrophysiol. 2014;25:875–881.
   PubMed Web of Science ®Google Scholar
• Guarracino F, Cariello C, Danella A, et al. Right ventricular failure: physiology and assessment. Minerva Anestesiol. 2005;71:307–312.
   PubMedGoogle Scholar
• Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010.
   PubMed Web of Science ®Google Scholar
• Riina K, Jukka L, Juhani A, et al. Cardiac Sarcoidosis. Circulation. 2015;131:624–632.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. Eur Respir J. 2017;49:1601290.
   PubMed Web of Science ®Google Scholar
• Media Releases [Internet]. [cited 2020 Aug 20]. Available from: https://old.cbs.gov.il/reader/newhodaot/hodaa_template_eng.html?hodaa=201611404.
   Google Scholar
• Yigla M, Badarna‐Abu‐Ria N, Goralnik L, et al. Sarcoidosis in residents of northern Israel of Arabic and Jewish origin: a comparative study. Respirology. 2006;11:586–591.
   PubMed Web of Science ®Google Scholar
• Tiosano S, Nir Z, Gendelman O, et al. The association between systemic lupus erythematosus and bipolar disorder – a big data analysis. Eur Psychiatry. 2017;43:116–119.
   PubMed Web of Science ®Google Scholar
• Tiosano S, Versini M, Dar Antaki L, et al. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study. Clin Immunol. 2019;199:57–61.
   PubMed Web of Science ®Google Scholar
• Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am. 2004;88:1145–1172.
   PubMed Web of Science ®Google Scholar
• He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002.
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Bell SC, Branson RD, et al. Control of confounding and reporting of results in causal inference studies. guidance for authors from editors of respiratory, sleep, and critical care. J Ann ATS. 2018;16:22–28.
   Web of Science ®Google Scholar
• Textor J, van der Zander B, Gilthorpe MS, et al. Robust causal inference using directed acyclic graphs: the R package ‘dagitty.’. Int J Epidemiol. 2016;45:1887–1894.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of Sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–1889.
   PubMed Web of Science ®Google Scholar
• Hillerdal G, Nöu E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. Am Rev Respir Dis. 1984;130:29–32.
   PubMed Web of Science ®Google Scholar
• Wu C-H, Chung P-I, Wu C-Y, et al. Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case-control study in Taiwan. J Dermatol. 2017;44:423–430.
   PubMed Web of Science ®Google Scholar
• Beghè D, Dall’Asta L, Garavelli C, et al. Sarcoidosis in an Italian province. Prevalence and environmental risk factors. Zissel G, editor. PLoS ONE. 2017;12:e0176859.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Jacobsen SJ, John C, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Wijarnpreecha K, Cheungpasitporn W, et al. Inpatient prevalence, expenditures, and comorbidities of Sarcoidosis: nationwide inpatient sample 2013–2014. Lung. 2019;197:165–171.
   PubMed Web of Science ®Google Scholar
• Mahmoud AR, Dahy A, Dibas M, et al. Association between sarcoidosis and cardiovascular comorbidity: A systematic review and meta-analysis. Heart Lung. Internet]. 2020 [cited 2020 May 21]. Available from: http://www.sciencedirect.com/science/article/pii/S0147956320301011
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183:1524–1530.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Maucort-Boulch D, Kerever S, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J. 2016;48:1700–1709.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Who dies from sarcoidosis and why? Am J Respir Crit Care Med. 2011;183:1446–1447.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failureThe task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;2016(37):2129–2200.
   Web of Science ®Google Scholar
• Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis: diagnosis and treatment. Curr Opin Cardiol. 2012;27:181–189.
   PubMed Web of Science ®Google Scholar
• Mambretti J. Chest X-ray Stages of Sarcoidosis. J Insur Med. 2004;36:91–92.
   PubMedGoogle Scholar
• Baughman RP, Costabel U, Du Bois RM. Treatment of Sarcoidosis. Clin Chest Med. 2008;29:533–548.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol. 2012;8:95–103.
   PubMed Web of Science ®Google Scholar
• Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16:505–511.
   PubMed Web of Science ®Google Scholar
• Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J. 1994;70:863–870.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952.
   PubMed Web of Science ®Google Scholar
• Drent M, Lower EE, Vries JD. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40:255–263.
   PubMed Web of Science ®Google Scholar
• Drent M, Strookappe B, Hoitsma E, et al. Consequences of Sarcoidosis. Clin Chest Med. 2015;36:727–737.
   PubMed Web of Science ®Google Scholar
• Nayor M, Vasan RS. Preventing heart failure: the role of physical activity. Curr Opin Cardiol. 2015;30:543–550.
   PubMed Web of Science ®Google Scholar
• Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999;99:1173–1182.
   PubMed Web of Science ®Google Scholar